Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $34.95 Consensus PT from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-one ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $34.95.

A number of analysts recently weighed in on NTLA shares. Truist Financial reduced their target price on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Wolfe Research raised shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective for the company in a research note on Monday, April 21st. Wall Street Zen raised shares of Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Citigroup cut their price target on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Finally, Guggenheim cut their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, May 12th.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA traded down $0.09 during trading hours on Wednesday, hitting $7.58. The stock had a trading volume of 4,328,005 shares, compared to its average volume of 2,735,365. The stock's fifty day simple moving average is $7.90 and its 200 day simple moving average is $10.17. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.18. The firm has a market capitalization of $785.16 million, a price-to-earnings ratio of -1.39 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. During the same quarter in the previous year, the business posted ($1.12) EPS. Intellia Therapeutics's revenue for the quarter was down 42.6% compared to the same quarter last year. As a group, research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NTLA. Regeneron Pharmaceuticals Inc. bought a new position in shares of Intellia Therapeutics during the 4th quarter worth about $43,177,000. Voloridge Investment Management LLC increased its stake in Intellia Therapeutics by 226.8% in the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock valued at $17,805,000 after acquiring an additional 1,059,751 shares during the period. Contrarius Group Holdings Ltd bought a new stake in Intellia Therapeutics in the fourth quarter valued at about $11,798,000. Two Sigma Advisers LP increased its stake in Intellia Therapeutics by 94.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after acquiring an additional 970,700 shares during the period. Finally, Two Sigma Investments LP increased its stake in Intellia Therapeutics by 88.1% in the fourth quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock valued at $21,498,000 after acquiring an additional 863,363 shares during the period. Institutional investors own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.